HomeQuestion
Would you consider splenic radiation in stage IV CD5+ DLBCL involving the bone marrow in patients who initially presented with symptomatic splenomegaly, anemia, and thrombocytopenia but achieved complete response on PET after 6 cycles of R-miniCHOP?
2 Answers
Mednet Member
Radiation Oncology · Duke University Medical Center
CD5 positivity is an adverse prognostic factor in DLBCL. About 5% of patients with DLBCL are CD5+. Other adverse risk factors are often present in these patients (advanced age, non-germinal center histology, high IPI, etc.).
More generally speaking, the role of consolidation RT in advanced DLBCL is ...